S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PYPL   73.30 (-0.79%)
PFE   40.22 (-0.42%)
NFLX   327.66 (-0.22%)
NASDAQ:AMTX

Aemetis - AMTX Stock Forecast, Price & News

$2.72
+0.11 (+4.21%)
(As of 03/27/2023 05:16 PM ET)
Add
Compare
Today's Range
$2.61
$2.76
50-Day Range
$2.60
$4.93
52-Week Range
$2.51
$13.78
Volume
381,150 shs
Average Volume
561,975 shs
Market Capitalization
$99.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.05

Aemetis MarketRank™ Forecast

Analyst Rating
Hold
2.20 Rating Score
Upside/​Downside
379.8% Upside
$13.05 Price Target
Short Interest
Bearish
20.71% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Aemetis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to $0.29 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Oils/Energy Sector

207th out of 242 stocks

Industrial Organic Chemicals Industry

16th out of 20 stocks


AMTX stock logo

About Aemetis (NASDAQ:AMTX) Stock

Aemetis, Inc. is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota. The India segment refers to the Kakinada plant, administrative offices in Hyderabad, and holding companies in Nevada and Mauritius. Its products include glycerin, ethanol, food and feed, biodiesel, and edible oils. The company was founded by Eric Armstrong McAfee in 2006 and is headquartered in Cupertino, CA.

Receive AMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

AMTX Stock News Headlines

Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
Aemetis Begins Construction of Keyes Plant Solar Microgrid
Aemetis Reports Third Quarter 2022 Financial Results
Aemetis (AMTX) Reports Q3 Loss, Tops Revenue Estimates
Aemetis (NASDAQ:AMTX) Stock Rating Upgraded by StockNews.com
See More Headlines
Receive AMTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

AMTX Company Calendar

Last Earnings
11/11/2021
Today
3/27/2023
Next Earnings (Estimated)
5/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
N/A
Current Symbol
NASDAQ:AMTX
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.05
High Stock Price Forecast
$27.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+379.8%
Consensus Rating
Hold
Rating Score (0-4)
2.20
Research Coverage
5 Analysts

Profitability

Net Income
$-107,760,000.00
Pretax Margin
-41.60%

Debt

Sales & Book Value

Annual Sales
$256.51 million
Book Value
($5.76) per share

Miscellaneous

Free Float
31,396,000
Market Cap
$99.69 million
Optionable
Not Optionable
Beta
0.87

Key Executives

  • Eric Armstrong McAfee
    Chairman & Chief Executive Officer
  • Todd A. WaltzTodd A. Waltz
    Chief Financial Officer, Secretary & Executive VP
  • Andrew B. FosterAndrew B. Foster
    Executive VP & President-Advanced Fuels Business
  • Sanjeev GuptaSanjeev Gupta
    Executive President-Aemetis International













AMTX Stock - Frequently Asked Questions

Should I buy or sell Aemetis stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AMTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMTX, but not buy additional shares or sell existing shares.
View AMTX analyst ratings
or view top-rated stocks.

What is Aemetis' stock price forecast for 2023?

5 equities research analysts have issued 1-year price targets for Aemetis' shares. Their AMTX share price forecasts range from $3.00 to $27.00. On average, they predict the company's share price to reach $13.05 in the next year. This suggests a possible upside of 379.8% from the stock's current price.
View analysts price targets for AMTX
or view top-rated stocks among Wall Street analysts.

How have AMTX shares performed in 2023?

Aemetis' stock was trading at $3.96 at the beginning of 2023. Since then, AMTX shares have decreased by 31.3% and is now trading at $2.72.
View the best growth stocks for 2023 here
.

Are investors shorting Aemetis?

Aemetis saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 7,590,000 shares, an increase of 10.6% from the February 28th total of 6,860,000 shares. Based on an average daily trading volume, of 560,300 shares, the short-interest ratio is presently 13.5 days.
View Aemetis' Short Interest
.

When is Aemetis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023.
View our AMTX earnings forecast
.

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) announced its quarterly earnings results on Thursday, November, 11th. The specialty chemicals company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.25. The specialty chemicals company had revenue of $49.90 million for the quarter, compared to analyst estimates of $54.23 million. During the same period last year, the company earned ($0.59) EPS.

What ETF holds Aemetis' stock ?

Strategy Shares Halt Climate Change ETF holds 278 shares of AMTX stock, representing 0.08% of its portfolio.

What other stocks do shareholders of Aemetis own?
What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by many different retail and institutional investors. Top institutional investors include Encompass Capital Advisors LLC (5.08%), Alliancebernstein L.P. (4.90%), Millennium Management LLC (2.87%), Geode Capital Management LLC (1.67%), Morgan Stanley (1.48%) and Thomist Capital Management LP (1.37%). Insiders that own company stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends
.

How do I buy shares of Aemetis?

Shares of AMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $2.72.

How much money does Aemetis make?

Aemetis (NASDAQ:AMTX) has a market capitalization of $99.69 million and generates $256.51 million in revenue each year. The specialty chemicals company earns $-107,760,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.

How many employees does Aemetis have?

The company employs 158 workers across the globe.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The official website for the company is www.aemetis.com. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at investors@aemetis.com, or via fax at 408-252-8044.

This page (NASDAQ:AMTX) was last updated on 3/27/2023 by MarketBeat.com Staff